Allen Cunningham (L) and Shaharyar Khan (Rivus)
Taking on Big Pharma-sized indications, tiny biotech claims early win in fat loss. Will it translate to diabetes, NASH and beyond?
As Big Pharma races to beef up their franchises in cardiometabolic diseases, a much smaller player wants to give them a run for their money …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
